Yungshin’s Entecavir Tablet Was Approved by Ministry of Health, Labour and Welfare for Marketing in Japan in February 2017

 Clonidine Tablet Was Approved for Marketing in Australia and Canada in November 2016 and March 2017 Respectively
Yungshin’s Entecavir Tablet, the vertically integrated drug for chronic hepatitis B, was approved by Ministry of Health, Labour and Welfare of Japan on February 15, 2017. Yungshin is the first batch of the drug manufacturers that obtain the permit license of generic drugs.

Hepatitis B is a worldwide disease, mainly breaking out in Asia, Africa, Southern Europe and Latin America. Some patients inhibit the virus after the mild onset of Hepatitis B, while some patients will suffer from a long-term infection. Entecavir tablet is an antiviral drug that inhibits the viral replication of adults with chronic HBV infection more effectively than Lamivudine.

After the price is obtained, this product is expected to be marketed in Japan this May, carving up the business opportunity of JPY 1 billion. 

After Clonidine Tablet was marketed successfully in the U.S. in 2013, Yungshin applied for the registration of Clonidine Tablet in Canada, Australia and New Zealand with an aim to provide the best drugs improving health. In November 2016 and March 2017, Clonidine Tablet was approved for marketing in Australia and Canada respectively.

Currently, Clonidine Tablet is the most widely used antihypertensive drug, which mainly suppresses the control center responsible for vasoconstriction and enables vasodilatation indirectly. This drug is commonly used to treat mild-to-moderate hypertension and can be used alone or in combination with other antihypertensive agents. The drug can also be used to prevent the occurrence of migraine.